Quarterly report pursuant to Section 13 or 15(d)

6. Commitments and Contingencies (Details Narrative)

v2.4.0.8
6. Commitments and Contingencies (Details Narrative) (USD $)
3 Months Ended 6 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Mar. 31, 2014
Potential severance under certain employment agreements     $ 1,130,000    
Aggregated annual salaries under certain employment agreements 935,000   935,000    
Product revenue 2,695,000 3,456,000 5,491,000 6,177,000  
Vetericyn and Innovacyn [Member]
         
Product revenue 459,000 1,289,000 987,000 2,030,000  
Accounts receivable 117,000   117,000   220,000
More Pharma [Member]
         
Accounts receivable 1,201,000   1,201,000   790,000
Transaction costs 16,000 16,000 32,000 32,000  
Amortization of upfront fees (transaction costs) $ 378,000 $ 378,000 $ 752,000 $ 752,000